CoChat
Sign Up
Cited by 176Adrenal and Paraganglionic TumorsRenal cell carcinoma treatmentNeuroendocrine Tumor Research Advances

Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma

Reibetanz, Joachim, Jurowich, Christian, Erdogan, Ilknur, Nies, Christoph, Rayes, Nada, Dralle, Henning, Behrend, Matthias, Allolio, Bruno +1 more·2012·Annals of Surgery
DOI 10.1097/sla.0b013e3182367ac3
Open this paper in CoChat — free account

Abstract

OBJECTIVE: Adrenocortical carcinoma (ACC) is a rare malignancy with an unfavorable prognosis. The impact of a locoregional lymph node dissection (LND) has never been defined in this disease. We report the disease-specific outcome of patients treated with or without LND during primary adrenalectomy. METHODS: The medical records of patients followed by the German ACC Registry were retrospectively reviewed. Patients with incomplete resection or distant metastases were excluded. Only if the histologic analysis retrieved 5 or more lymph nodes, an intended LND was assumed (LND group). The predefined primary end point of the study was disease-specific survival. RESULTS: Of 283 included patients, 47 patients (16.6%) were treated with LND, whereas 236 patients (83.4%) underwent surgery without LND. Patients who underwent LND had a larger median tumor size (12.0 cm, range: 2.3-30 cm vs 10.0 cm, range: 4.0-39 cm, P = 0.007) and were more often treated by multivisceral resection (LND: 47.8% vs no-LND: 18.1%; P < 0.001). The other baseline characteristics (age, sex, endocrine activity, Weiss score, Ki-67 index, and adjuvant treatment) did not differ significantly. Median follow-up of all patients still alive was 40 months (range: 6-326). Multivariate analysis adjusted for age, tumor stage, multivisceral resection, adjuvant treatment, and lymph nodes status on preoperative imaging demonstrated a significantly reduced risk for tumor recurrence (hazard ratio: 0.65; 95% confidence interval: 0.43-0.98; P = 0.042) and for disease-related death (hazard ratio: 0.54; 95% confidence interval: 0.29-0.99; P = 0.049) in LND patients when compared with no-LND patients. CONCLUSIONS: Our retrospective data indicate that locoregional LND improves tumor staging and leads to a favorable oncologic outcome in patients with localized ACC.

Integrity signals

Registry

Crossref · 10.1097/sla.0b013e3182367ac3

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Emerging evidence from the surgical literature suggests adequate lymph node dissection at the time of adrenalectomy likely improves both rates of disease recurrence and survival.

    “Furthermore, there is emerging evidence from the surgical literature that adequate lymph node dissection at the time of adrenalectomy likely improves both rates of disease recurrence and survival (249).”

    From Adrenocortical carcinoma (2014) · cites this paper as [249]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Reibetanz, J., Jurowich, C., Erdogan, I., Nies, C., Rayes, N., Dralle, H., Behrend, M., Allolio, B., & Fassnacht, M.
Affiliations
  • University of Würzburg (DE)
  • Marienhospital Osnabrück (DE)
  • Charité – Universitätsmedizin Berlin (DE)
  • University Hospital in Halle (DE)
Corresponding author
  • Reibetanz, Joachim
  • Jurowich, Christian
ORCID
Venue
Annals of Surgery
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2012-02
Volume
255
Issue
2
Pages
363-369
ISSN
0003-4932 (ISSN-L)
DOI
10.1097/sla.0b013e3182367ac3
OpenAlex
W2074531404
Cited by
176
References
39
Citations by year
2026: 4 · 2025: 9 · 2024: 8 · 2023: 10 · 2022: 8 · 2021: 17 · 2020: 11 · 2019: 9 · 2018: 14 · 2017: 13 · 2016: 14 · 2015: 20 · 2014: 13 · 2013: 10 · 2012: 13
FWCI
12.33
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of Surgery (publishedVersion)
  • PubMed (publishedVersion)
Funders
Julius-Maximilians-Universität Würzburg
Topics
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
Keywords
adrenocortical carcinoma, lymph node dissection, adrenalectomy, disease-specific survival, tumor recurrence, multivisceral resection, tumor staging, oncological outcomes
MeSH terms
Adolescent, Adrenal Cortex, Adrenal Cortex Neoplasms, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Infant, Lymph Node Excision, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Recurrence, Retrospective Studies, Survival Analysis, Treatment Outcome, Adrenocortical Carcinoma, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review